- Home
- HSII vs NBTX Comparison
HSII vs NBTX Comparison
Compare HSII & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSII
- NBTX
- Stock Information
- Founded
- HSII 1953
- NBTX 2003
- Country
- HSII United States
- NBTX France
- Employees
- HSII N/A
- NBTX N/A
- Industry
- HSII Diversified Commercial Services
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- HSII Consumer Discretionary
- NBTX Health Care
- Exchange
- HSII Nasdaq
- NBTX Nasdaq
- Market Cap
- HSII 1.0B
- NBTX 868.8M
- IPO Year
- HSII 1999
- NBTX 2020
- Fundamental
- Price
- HSII $58.23
- NBTX $29.69
- Analyst Decision
- HSII Buy
- NBTX Strong Buy
- Analyst Count
- HSII 2
- NBTX 1
- Target Price
- HSII $57.50
- NBTX $8.00
- AVG Volume (30 Days)
- HSII 434.6K
- NBTX 157.9K
- Earning Date
- HSII 11-03-2025
- NBTX 09-30-2025
- Dividend Yield
- HSII 1.03%
- NBTX N/A
- EPS Growth
- HSII N/A
- NBTX N/A
- EPS
- HSII 1.60
- NBTX N/A
- Revenue
- HSII $1,155,576,000.00
- NBTX $11,930,711.00
- Revenue This Year
- HSII $11.42
- NBTX N/A
- Revenue Next Year
- HSII $1.96
- NBTX $114.97
- P/E Ratio
- HSII $36.31
- NBTX N/A
- Revenue Growth
- HSII 9.00
- NBTX N/A
- 52 Week Low
- HSII $36.87
- NBTX $2.76
- 52 Week High
- HSII $58.43
- NBTX $30.23
- Technical
- Relative Strength Index (RSI)
- HSII 77.16
- NBTX 72.00
- Support Level
- HSII $58.03
- NBTX $23.31
- Resistance Level
- HSII $58.31
- NBTX $30.23
- Average True Range (ATR)
- HSII 0.65
- NBTX 2.11
- MACD
- HSII 0.85
- NBTX 0.99
- Stochastic Oscillator
- HSII 98.13
- NBTX 96.61
About HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments include the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.